ASSESSING THE RELATIONSHIP BETWEEN LEFT VENTRICULAR HYPERTROPHY (LVH) AND ANTIHYPERTENSIVE TREATMENT OUTCOMES IN HYPERTENSIVE PATIENTS

Objective: The aim of this study was to determine the prevalence rate of left ventricular hypertrophy (LVH) in hypertensive patients and assess the usefulness of antihypertensive therapies in preventing the progression of LVH. Study Design: Observational Place and Duration: This study was conducted at, People’s University of Medical and Health Sciences Nawabshah (PUMHS) for a period of 1 year from March 2024 to March 2025. Methods: In this study  250 hypertension patients were included; 125 of them had regulated blood pressure (≤130/80 mm Hg) and 125 had uncontrolled blood pressure (≥140/90 mm Hg). Using transthoracic echocardiography, echocardiographic parameters such as left ventricular mass (LVM), interventricular septum (IVS), posterior wall thickness (PWT), and left ventricular internal diameter (LVID) were evaluated. Data were analyzed using SPSS version 26.0, with comparisons made using the Student’s t-test. Results: In the uncontrolled hypertension group, the mean LVM was 155 g, significantly higher than the controlled group’s 55 g (p < 0.001). Other parameters, such as LVMI (87 g/m² vs. 70 g/m²), IVS (11.1 mm vs. 5.5 mm), PWT (11.1 mm vs. 3.6 mm), and EF% (40% vs. 45%), also showed significant differences (all p < 0.05). While the uncontrolled group received CCBs more often (40%) than the controlled group (20%), the controlled group was prescribed ACE inhibitors/ARBs more frequently (60%) than the uncontrolled group (40%). Conclusion: The study demonstrated that uncontrolled hypertension is strongly associated with LVH, with significantly higher LVM and adverse echocardiographic outcomes. ACE inhibitors/ARBs were effective for the controlled hypertensive group, and CCBs were used regularly in the uncontrolled hypertensive group. Blood pressure control, coupled with medication and lifestyle interventions, can significantly help in the prevention of LVH progression.